ArticleScientific reports2026
AI based prediction of severe exacerbation in Asian bronchiectasis patients using the KMBARC registry.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Classical scoring tools such as the Bronchiectasis Severity Index (BSI) and FACED have shown good performance for predicting adverse outcomes, yet they were developed using European cohorts and may not fully align with Asian clinical characteristics. This study aimed to develop an Asian population–specific artificial intelligence (AI) model for predicting severe acute exacerbations (AEs) in bronchiectasis. A total of 492 patients with 1-year follow-up data from the Korean Multicenter Bronchiectasis Audit and Research Collaboration registry were analyzed. Severe AE was defined as an event requiring an emergency department visit or hospitalization due to worsening respiratory symptoms. Three AI models—extreme gradient boosting, logistic regression, and multilayer perceptron (MLP)—were trained and compared with classical scoring models. Severe AE occurred in 56 patients (11.4%). Among the models, the MLP demonstrated the best performance, with higher sensitivity, specificity, F1-score, and area under the receiver operating characteristic curve compared with both classical scores. Shapley additive explanation (SHAP) analysis identified BSI, sputum characteristics, and histories of tuberculosis and pneumonia as key predictors. Although classical scores performed well, a population-specific AI model using local clinical data showed improved predictive performance and may support individualized risk assessment for Asian patients with bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.